AbbVie (ABBV) said Thursday that it has submitted a biologics license application to the US Food and Drug Administration for trenibotulinumtoxinE to treat moderate to severe glabellar lines.

The biopharmaceutical company said the application is supported by data from two pivotal phase 3 clinical studies evaluating TrenibotE, which met all primary and secondary endpoints.

AbbVie shares were down 0.1% in recent trading.

Price: 177.56, Change: +0.50, Percent Change: +0.29